PBM Rebate Economics: Why Your Copay Isn't the List Price

Why is your GLP-1 copay higher than the cash-pay price? PBM rebate economics explain the gap between list prices, net prices, and what patients actually pay.

One of the most counterintuitive aspects of U.S. drug pricing is that the list price a pharmaceutical manufacturer sets — the number reported in news stories and financial documents — often bears little relationship to the actual net price the manufacturer receives. The gap between list and net is filled with rebates, discounts, and fees paid to pharmacy benefit managers (PBMs), health plans, and other intermediaries. For GLP-1 medications in 2026, understanding the PBM rebate flow is essential to understanding why your copay is what it is — and why the cash-pay prices have fallen so dramatically.

How PBM Rebates Actually Work

A pharmaceutical manufacturer negotiates with pharmacy benefit managers (CVS Caremark, Express Scripts, OptumRx, and others) and health plans directly. The manufacturer sets a list price (also called the wholesale acquisition cost, WAC) that the pharmacy pays the wholesaler. When the pharmacy dispenses the medication, the insurance plan or PBM pays the pharmacy (minus the patient copay). Later, the manufacturer pays a rebate back to the PBM or health plan based on a negotiated percentage of the list price.

The rebate flow is opaque, varies by drug class and plan, and is governed by confidential commercial agreements. But for branded specialty drugs in competitive categories — GLP-1s, specialty autoimmune drugs, certain oncology categories — the rebate amounts can represent 40-70% of the list price. A drug with a $1,300 list price might have a net manufacturer price of $400-$800 after rebates flow back through the system.

Why This Matters for Copays

The patient's copay or coinsurance is typically calculated based on the list price or a plan-specific formulary tier, not the net price. That means patients with 20% coinsurance on a $1,300 drug are paying $260 toward a drug that nets the manufacturer perhaps $500 after rebates. The rebate flows to the PBM and plan, which use it (in principle) to reduce premium costs for the broader insured population — but the individual patient's cost-sharing does not benefit from the specific rebate on their drug.

Why Cash-Pay Programs Can Be Cheaper Than Insurance

When a manufacturer offers a direct cash-pay program (NovoCare at $349, LillyDirect Zepbound vials at $299-$449), the manufacturer is bypassing the PBM rebate system entirely. The net revenue per unit is lower — sometimes substantially lower — than the net revenue through the commercial insurance channel. But the manufacturer gains direct customer relationships, volume from uninsured patients, and insulation from increasing PBM negotiating leverage.

For the patient, the comparison is between the net cash-pay price ($249-$349 for Wegovy) and the insurance-plan copay for the same drug. In some cases the insurance copay is lower than the cash-pay price (especially for patients with strong commercial plans); in other cases the cash-pay price is lower, particularly for patients with high-deductible plans or plans with weight-management exclusions.

The 340B and Medicaid Complication

Government pricing programs — 340B for safety-net hospitals, Medicaid best-price rules, Veterans Affairs Federal Supply Schedule — operate under statutory pricing formulas rather than commercial negotiations. Manufacturers must offer these prices, which are generally deeply discounted from list. The interaction between commercial rebates and government pricing rules creates complex incentives for manufacturers, and is one reason pricing policy debates are technically challenging to navigate.

Implications for 2026-2027 GLP-1 Pricing

As Medicare negotiated pricing takes effect in 2027 and as cash-pay programs continue to expand, the PBM rebate system's role in GLP-1 pricing is likely to shrink. Medicare's negotiated price is a transparent, government-set number that doesn't flow through PBM rebates. Manufacturer direct-to-consumer programs bypass PBMs entirely. The traditional list-price-minus-rebate commercial model will continue to exist but will cover a shrinking share of total GLP-1 volume.

For patients, this matters because pricing transparency is increasing. Patients can compare a published cash-pay price ($349 NovoCare, $299-$449 Zepbound vial, $249 telehealth subscription) against their plan copay and make a rational decision. That transparency was simply not available in the traditional list-price/rebate system. For related reporting, see our Medicare negotiation analysis and employer health plan coverage review.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.